Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon to Identify Multiple Sclerosis Biomarkers for CDC

NEW YORK, Oct. 27 (GenomeWeb News) - Metabolon will identify disease biomarkers for multiple sclerosis for the US Centers for Disease Control and Prevention, the company said yesterday.


MS is an autoimmune disease that affects the central nervous system by destroying myelin, the protective fatty tissue covering nerve fibers.  Without myelin, nerves are unable to transmit signals to and from the brain.  It is estimated that more than 2.5 million people worldwide are affected by MS, with more than 400,000 diagnosed in the United Stateseach year.


John Ryals, president and CEO of Metabolon, said the company hopes to use metabolomics to find biomarkers that will determine a cause for the disease and that can be used to create a definitive diagnostic tool for it.


Financial terms of the research were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.